Investors should consider MGM Resorts International (MGM) as a value play, with a "floor" set by a recent $48/share bid and a long-term price target of $150+ driven by massive expansion in Japan and Dubai. In the energy sector, Talen Energy (TLN) offers a high-conviction opportunity to play the AI power crunch; it currently trades below its replacement value and could reach $750 to $1,050 per share as hyperscalers scramble for nuclear power. For high-risk biotech exposure, Actis Oncology (AKTS) is a prime acquisition target for Big Pharma with critical clinical data expected in Q1 2025 that could drive the stock toward $200. Speculative investors can look at the $GEOD token, a decentralized infrastructure project providing 2cm GPS accuracy for John Deere and DJI drones, which uses 80% of revenue for token buybacks. Overall, the most actionable strategy is to focus on "hard assets" like nuclear power and strategic real estate that serve as the essential infrastructure for the burgeoning AI and robotics era.

MGM Resorts International (MGM)

• Investment Thesis: A "simple math" play focused on hidden international assets and a floor set by a major financial buyer. • Key Drivers: * The "Diller Floor": Barry Diller (IAC) owns 26% of the company and recently bid $48/share. The presenter argues Diller is a "financial buyer" looking to get rich, suggesting the company is now "in play." * Japan Opportunity: MGM has a license for a casino in Osaka (opening 2030). The Japanese gambling market is estimated at $40B (vs. Vegas at $10B). Its proximity to Shanghai and Beijing makes it a prime destination for Chinese high-rollers. * Dubai Optionality: MGM is building a non-gaming complex in Dubai with 300,000 sq. ft. of "empty space" reserved in case gambling is legalized. * Share Buybacks: The company has aggressively bought back half of its float in the last six years.

Takeaways

• Price Target: Presenter estimates a "triple" potential. Breakdown: Vegas assets (~$60) + Japan (~$50) + Dubai option (~$40-$50) = $150+ potential. • Action: "Don't tender" shares to the current $48 bid; the presenter believes the stock is worth significantly more. • Risk/Reward: High floor due to the Diller bid with massive upside from Asian expansion.

Talen Energy (TLN)

• Investment Thesis: A play on the "Power Cycle" driven by AI data center demand and the scarcity of firm, carbon-free baseload power. • Key Drivers: * Asset Value: Owns 2GW of nuclear and 6GW of natural gas power. * Replacement Cost: Currently trading at a $25B enterprise value, while the cost to rebuild these assets today is estimated at $45B. * The "Microsoft/Constellation" Precedent: Microsoft recently paid a massive premium to restart a nuclear reactor at Three Mile Island, signaling that "hyperscalers" (Amazon, Google, Meta) are in a panic to secure 24/7 power. * Data Center Co-location: Talen has a contract with Amazon for a data center directly connected to its nuclear plant, allowing for premium power pricing.

Takeaways

• Valuation Scenarios: * Base Case: $50/share free cash flow (FCF) by just running the business = ~$750 stock (at 15x multiple). * Bull Case: $70/share FCF with more data center deals = $1,050 stock. * Super Bull Case: $100/share FCF if they build new capacity = $1,500+ stock. • Action: Buy shares as a "hard asset" play that is currently trading below its replacement value.

Actis Oncology (AKTS)

• Investment Thesis: A biotech play on Radiopharmaceuticals—described as "micro-drones" that deliver radioactive payloads directly to cancer cells with minimal collateral damage. • Key Drivers: * Strategic Backing: Eli Lilly backstopped their $300M IPO with a $100M order. * The "Moat": Uses Actinium, a radioisotope derived from U.S. nuclear waste. This supply chain is difficult for competitors (especially in China) to replicate. * De-risked Tech: Physicians can use imaging to see the drug hitting the target in early trials, reducing the "guesswork" of traditional drug development. * M&A Heat: Big Pharma (Novartis, Bristol Myers, Bayer) has spent $15B on radiotherapy acquisitions recently.

Takeaways

• Timeline: Initial clinical data for lead programs (Nectin-4 and B7H3) expected in Q1 2025. • Valuation: Currently a ~$1B market cap; presenter suggests it could be worth $10B ($200/share) if one program succeeds. • Risk: High volatility; typical biotech "binary" risk where the stock could drop significantly on bad data.

GeoNet (GEOD)

• Investment Thesis: A decentralized "DePIN" (Decentralized Physical Infrastructure Network) project on the Solana blockchain providing high-precision location data for AI and robotics. • Key Drivers: * Precision: Uses RTK technology to provide 2cm accuracy (vs. 2 meters for standard GPS). * Network Effect: 22,000+ base stations deployed by hobbyists in 150 countries. It is already 2x the size of legacy competitors like Trimble or Hexagon. * Real-World Customers: Used by DJI (drones), John Deere (autonomous tractors), and TomTom (mapping). * Tokenomics: The network generates $11M ARR (growing 3x YoY). 80% of revenue is used to buy back the $GEOD token on the open market.

Takeaways

• Asset Type: Investment is in the $GEOD token, not company equity. • Valuation: Trading at a ~$150M fully diluted valuation. • Action: High-upside "lottery ticket" for those comfortable with crypto. It acts as a "natural monopoly" for the robotic/drone era.

Investment Themes & Sector Insights

1. The AI Power Crunch

• Insight: AI demand is "turbocharging" an existing power shortage. Investors should look for companies owning "firm baseload" (Nuclear/Gas) rather than just intermittent renewables. • Sector: Utilities and Independent Power Producers (IPPs).

2. Physical AI & Robotics

• Insight: As AI moves into the physical world (autonomous mowers, drones, "robotic mules" in ag), the infrastructure for precise geolocation and high-density power becomes the "picks and shovels" of the industry.

3. Biotech Longevity & GLP-1s

• Insight: The panel noted that GLP-1s (obesity drugs) are effectively the first mass-market "longevity drugs" due to caloric restriction. This is shifting public perception toward pharmaceutical intervention for healthy living.

4. Regulatory Risks

• Risk Factor: For power (Talen) and gambling (MGM), the primary risk is government intervention—either through price caps on electricity to protect consumers or changes in international gaming licenses.